Werewolf Therapeutics, Inc. (HOWL) News
Follow Werewolf Therapeutics, Inc. (HOWL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
HOWL shares jump 150% as M&A headlines emerge
HOWL resumes trading higher by 150% after M&A headlines, alongside prior license headlines from EMD for WTX-124 and WTX-330 development late yesterday.
EQUITY | Aug 21, 2026, 12:22 PM UTC
M
Werewolf Therapeutics, Ambros Therapeutics announce merger and $150 million placement
Werewolf Therapeutics and Ambros Therapeutics announce a merger agreement and a concurrent oversubscribed $150 million private placement.
MNA | Aug 21, 2026, 12:09 PM UTC
L
HOWL trading halted pending news
Hammerstone MarketTalk reports that HOWL is halted for news, with no magnitude, reason, or expected timing provided in the alert.
REGULATION | Aug 21, 2026, 12:06 PM UTC
M
Werewolf Therapeutics to merge with Ambros in stock deal
Werewolf Therapeutics says stockholders would own 6.8% of the combined company, Ambros stockholders 71.7% and private placement investors 21.5%, with closing expected by Q1 2027 subject to approvals.
MNA | Aug 21, 2026, 12:02 PM UTC
M
Werewolf Therapeutics, Ambros Therapeutics agree merger, $150 million placement
Werewolf Therapeutics and Ambros Therapeutics announce a merger agreement and a concurrent oversubscribed $150 million private placement.
MNA | Aug 21, 2026, 12:00 PM UTC
M
HOWL Werewolf Therapeutics to operate as Ambros; trade as AMBX
HOWL Werewolf Therapeutics will operate as Ambros Therapeutics and will trade on Nasdaq under the ticker AMBX, according to Hammerstone MarketTalk.
MNA | Aug 21, 2026, 12:00 PM UTC
M
Werewolf Therapeutics announces merger and $150M private placement
Werewolf Therapeutics and ambros Therapeutics announce a merger agreement and a concurrent oversubscribed $150M private placement.
MNA | Aug 21, 2026, 12:00 PM UTC
M
Premarket gainers list led by RFAI, RFAIR and HOWL
TradeXchange Newsdesk lists the top ten premarket percentage gainers, led by RFAI at +411.70%, RFAIR at +125.00% and HOWL at +76.57%, with no catalyst supplied.
EQUITY | Aug 21, 2026, 09:17 AM UTC
M
Werewolf Therapeutics obtains exclusive EMD license for WTX-124, WTX-330
Hammerstone MarketTalk reports that HOWL Werewolf Therapeutics obtains an exclusive license from EMD for the development of WTX-124 and WTX-330, as stated in an SEC filing.
REGULATION | Aug 20, 2026, 08:08 PM UTC
M
Werewolf Therapeutics files EMD deal for $28M upfront payment
Werewolf Therapeutics (HOWL) files an SEC disclosure stating EMD will pay $28M upfront and $5M upon completion of asset transfer, with terms tied to the asset move.
MNA | Aug 20, 2026, 08:08 PM UTC
M
Werewolf Therapeutics sells inducer and indukine platforms to EMD Serono
Werewolf Therapeutics says in an SEC filing that it sold its inducer and indukine platforms to EMD Serono on August 14.
MNA | Aug 20, 2026, 08:08 PM UTC
L
HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M,
HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M, Q2 Operating Income $7.158M
EARNINGS | Jul 31, 2026, 11:01 AM UTC
L
HOWL - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
HOWL - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
EARNINGS | Jul 31, 2026, 11:00 AM UTC